Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Update

Daré Bioscience, Inc. (NASDAQ:DARE) was the target of a large increase in short interest in September. As of September 30th, there was short interest totalling 38,800 shares, an increase of 9.6% from the September 15th total of 35,400 shares. Based on an average daily volume of 39,300 shares, the short-interest ratio is currently 1.0 days. Currently, 0.5% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, Maxim Group reissued a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th.

Daré Bioscience Trading Up 0.6 %

Shares of DARE traded up $0.02 during trading hours on Thursday, hitting $3.60. The company had a trading volume of 21,056 shares, compared to its average volume of 45,827. The company has a market capitalization of $30.32 million, a PE ratio of -0.94 and a beta of 1.39. Daré Bioscience has a one year low of $3.05 and a one year high of $7.56. The company’s fifty day moving average price is $3.40 and its two-hundred day moving average price is $4.06.

Daré Bioscience (NASDAQ:DARE) last released its quarterly earnings results on Monday, August 12th. The biotechnology company reported $1.52 EPS for the quarter, topping the consensus estimate of ($0.57) by $2.09. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.60 million. Analysts forecast that Daré Bioscience will post -0.27 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC increased its holdings in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 6.70% of the company’s stock.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.